In July 2023, trastuzumab deruxtecan was approved for the treatment of patients with metastatic disease who had undergone at least one previous systemic therapy, as well as those with unresectable or metastatic adult breast cancer who had low expression of HER-2 and who had experienced a relapse within six months of finishing adjuvant chemotherapy. Here, ERBB2 is linked to breast cancer.